CD4 and neoplasm: PITPNM3 knockdown with CD4-aptamer-PITPNM3-siRNA chimeras in naive CD4+ T cells in a humanized mouse tumor model significantly attenuated primary tumor cell survival in situ and lung metastasis by promoting antitumor immunity [40].